Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016

Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016
Published Jun 22, 2016
67 pages — Published Jun 22, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016, provides in depth analysis on Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted pipeline therapeutics.

The report provides comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF-8), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF-8)
- The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics and enlists all their major and minor projects
- The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF-8) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF-8)
- Identify the use of drugs for target identification and drug

  
Source:
Document ID
GMDHC0052TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Growth/Differentiation Factor 8 (Myostatin or GDF-8) Overview71
Therapeutics Development83
  Growth/Differentiation Factor 8 (Myostatin or GDF-8) Products under Development by Stage of Development81
  Growth/Differentiation Factor 8 (Myostatin or GDF-8) Products under Development by Therapy Area91
  Growth/Differentiation Factor 8 (Myostatin or GDF-8) Products under Development by Indication101
Growth/Differentiation Factor 8 (Myostatin or GDF-8) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Growth/Differentiation Factor 8 (Myostatin or GDF-8) Products under Development by Companies132
Growth/Differentiation Factor 8 (Myostatin or GDF-8) Therapeutics Assessment156
  Assessment by Monotherapy/Combination Products151
  Assessment by Mechanism of Action161
  Assessment by Route of Administration172
  Assessment by Molecule Type192
Growth/Differentiation Factor 8 (Myostatin or GDF-8) Companies Involved in Therapeutics Development219
  Acceleron Pharma, Inc.211
  Atara Biotherapeutics, Inc.221
  Bristol-Myers Squibb Company231
  Eli Lilly and Company241
  Milo Biotechnology LLC251
  Pfizer Inc.261
  Regeneron Pharmaceuticals, Inc.271
  Sarepta Therapeutics, Inc.281
  Scholar Rock, Inc.291
Growth/Differentiation Factor 8 (Myostatin or GDF-8) Drug Profiles3022
  AAV1-Foliistatin Drug Profile302
  AAV9-Follistatin Drug Profile321
  ACE-083 Drug Profile332
  ACE-2494 Drug Profile351
  ACE-2798 Drug Profile361
  Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD Drug Profile371
  ATA-842 Drug Profile381
  BMS-986089 Drug Profile391
  domagrozumab Drug Profile402
  landogrozumab Drug Profile421
  luspatercept Drug Profile436
  OSX-200 Drug Profile491
  SRK-015 Drug Profile501
  trevogrumab Drug Profile511
Growth/Differentiation Factor 8 (Myostatin or GDF-8) Dormant Projects521
Growth/Differentiation Factor 8 (Myostatin or GDF-8) Discontinued Products531
Growth/Differentiation Factor 8 (Myostatin or GDF-8) Featured News &Press Releases5412
  May 19, 2016: Acceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association541
  May 09, 2016: Follistatin Gene Therapy Increases Function in Inclusion Body Myositis Patients551
  Dec 07, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes551
  Dec 05, 2015: Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition561
  Dec 01, 2015: Acceleron Announces Oral Plenary Presentation for ACE-083 in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia and Muscle Wasting571
  Nov 05, 2015: Acceleron Announces New Data on Luspatercept at the 2015 American Society of Hematology Annual Meeting571
  Oct 23, 2015: Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event581
  Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-083 at the 20th International Annual Congress of the World Muscle Society591
  Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-2494 at the 20th International Annual Congress of the World Muscle Society601
  Sep 23, 2015: Scholar Rock Presents First Data for Niche Modulator Inhibiting Myostatin Activation and Announces SRK-015 as Lead Drug Program601
  Jun 12, 2015: Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association611
  Jun 09, 2015: Acceleron Pharma to Host Conference Call and Webcast to Review New Luspatercept Data Presented at the 20th Congress of the European Hematology Association621
  May 21, 2015: Acceleron to Present Luspatercept Clinical Trials at the 20th Congress of the European Hematology Association631
  May 18, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia631
  May 02, 2015: Luspatercept Data Presented at the 13th International Symposium on Myelodysplastic Syndromes642
Appendix662
  Methodology661
  Coverage661
  Secondary Research661
  Primary Research661
  Expert Panel Validation661
  Contact Us661
  Disclaimer671

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016" Jun 22, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Growth-Differentiation-Factor-8-Myostatin-or-GDF-8-Pipeline-Review-H1-2016-2088-15990>
  
APA:
Global Markets Direct - Market Research. (2016). Growth/Differentiation Factor 8 (Myostatin or GDF-8) - Pipeline Review, H1 2016 Jun 22, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Growth-Differentiation-Factor-8-Myostatin-or-GDF-8-Pipeline-Review-H1-2016-2088-15990>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.